Breaking Finance News

A statement released earlier today by Cann about Syros Pharmaceuticals Inc (NASDAQ:SYRS) bumps the target price to $28.00

Yesterday Syros Pharmaceuticals Inc (NASDAQ:SYRS) traded -6.06% lower at $14.19. The company’s 50-day moving average is $13.51 and its 200-day moving average is $13.07. The last stock close price is up 1.95% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 18,326 shares of the stock were exchanged, down from an average trading volume of 39,330

Cann upped the price target of Syros Pharmaceuticals Inc (NASDAQ:SYRS) to $28.00 indicating a possible upside of 0.97%.

See Chart Below

Syros Pharmaceuticals Inc (NASDAQ:SYRS)

Syros Pharmaceuticals Inc has a 52 week low of $8.16 and a 52 week high of $21.50 The company’s market cap is currently $0.

About Syros Pharmaceuticals Inc (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company's gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets. Its drug programs include SY-1425 and SY-1365. SY-1425 (tamibarotene) is an oral and selective agonist, or activator, of the transcription factor RARa. It is involved in advancing SY-1425 into genomically defined patient populations with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SY-1365 is a selective small molecule inhibitor of cyclin-dependent kinase 7 (CDK7), a transcriptional kinase. SY-1425 is approved as tamibarotene in Japan for the treatment of acute promyelocytic leukemia (APL), a form of AML. It is developing SY-1365 with a focus on various indications, such as acute leukemia, Small cell lung cancer and Triple negative breast cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.